Cargando…
Type 2 diabetes subgroups and potential medication strategies in relation to effects on insulin resistance and beta-cell function: A step toward personalised diabetes treatment?
BACKGROUND: Type 2 diabetes is a syndrome defined by hyperglycaemia that is the result of various degrees of pancreatic β-cell failure and reduced insulin sensitivity. Although diabetes can be caused by multiple metabolic dysfunctions, most patients are defined as having either type 1 or type 2 diab...
Autores principales: | Veelen, Anna, Erazo-Tapia, Edmundo, Oscarsson, Jan, Schrauwen, Patrick |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085543/ https://www.ncbi.nlm.nih.gov/pubmed/33387681 http://dx.doi.org/10.1016/j.molmet.2020.101158 |
Ejemplares similares
-
A randomized placebo-controlled clinical trial for pharmacological activation of BCAA catabolism in patients with type 2 diabetes
por: Vanweert, Froukje, et al.
Publicado: (2022) -
Differences in complication patterns in subgroups of type 2 diabetes according to insulin resistance and beta-cell function
por: Cho, Yongin, et al.
Publicado: (2022) -
Innovation in the imaging of perianal fistula: a step towards
personalised medicine
por: Sahnan, Kapil, et al.
Publicado: (2018) -
SNAP – A Large Step in the Move towards Personalised Dosing of Acetylcysteine
por: Chiew, Angela L., et al.
Publicado: (2019) -
Personalised prevention of type 2 diabetes
por: Wareham, Nicholas J.
Publicado: (2022)